Hibch, encoding 3-hydroxyisobutyryl-coenzyme A (CoA) hydrolase, is an enzyme implicated in a critical step of valine catabolism. This pathway is essential for normal cellular metabolism, and disruption can lead to various biological consequences [1-10].

Hibch deficiency (HIBCHD) is a rare mitochondrial disorder. Patients often present with neurological symptoms such as movement disorders, including dystonia, chorea, parkinsonism, myoclonus, tremors, and abnormal eye movements. Other manifestations can include motor delay, hypotonia, ataxia, seizures, poor feeding, and organic aciduria. Brain MRI may show signal abnormalities in the deep gray matter, especially the globus pallidi and cerebral peduncles [1, 2, 5-7, 9, 10].

In colorectal cancer, high Hibch expression is linked to poor survival, increased cell growth, resistant apoptosis, and decreased autophagy. A novel inhibitor SBF-1 targeting Hibch mitochondrial localization shows antitumor effects both in vitro and in vivo and can enhance the efficacy of anti-VEGF therapy [1].

In conclusion, Hibch is crucial for valine catabolism. Studies on Hibch-related disorders, especially those with neurological symptoms and in the context of colorectal cancer, have provided insights into its role in normal and disease states. Understanding Hibch's function may contribute to the development of new diagnostic and therapeutic strategies for related diseases.